GlassScriptPhysician profile
James L Schmitz
NPI 1881681864
$2,099.08
in general payments reported to CMS, 2019-2025
23 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $258 · 2021: $267 · 2022: $300 · 2023: $387 · 2024: $438 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $607.14 | 2019-2025 | Trulance, Uceris, Xifaxan |
| Exact Sciences Corporation | $209.44 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $123.33 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $110.89 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $105.57 | 2020-2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $103.75 | 2021-2022 | |
| Pfizer INC. | $100.63 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $98.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $80.75 | 2019-2022 | |
| Abbvie INC. | $78.44 | 2021-2023 | Vraylar, Ubrelvy |
| Merck Sharp & Dohme LLC | $68.91 | 2019-2021 | |
| Novo Nordisk INC | $64.50 | 2022-2024 | Rybelsus, Ozempic |
| Allergan, INC. | $64.03 | 2020 | |
| Antares Pharma, INC. | $61.63 | 2024-2025 | Xyosted |
| Abbott Laboratories | $50.19 | 2022-2023 | Freestyle Libre 2 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.81 | 2021-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.80 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $18.45 | 2024 | Voquezna |
| Eisai INC. | $16.95 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.80 | 2025 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $14.69 | 2022 | |
| Strongbridge US INC. | $14.46 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Schmitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.